conducted to assess the efficacy and safety of new indications or of investigational medicines. Two recently published RCTs in the top two internal medicine journals, conducted in the UK, exemplify the opposite extreme approaches taken by industry and academics when deciding to label as pragmatic a pre-licensing medicine RCT.
The first RCT, the Salford COPD trial, was published in 2016. This was an industry-sponsored multicenter trial to compare an investigational medication (fluticasone furoate and vilanterol) vs usual care in chronic obstructive pulmonary disease (COPD) [4] . This study was labeled as Bthe world's first phase 3 pragmatic RCT^(emphasis added) in COPD patients. Since 2012 on the registry (clinicaltrials.gov) and in all published reports since 2014, the terms Bpragmatic,^Breal-world,^Beffectiveness^(as opposed to efficacy [5] ), or Bnormal clinical practice^were repeatedly mentioned [6] . That this was a phase 3 trial was also mentioned in all reports, except in the article reporting the results. The assessment of this trial by means of the PRECIS-2 tool nine domains showed that the Salford COPD trial had few domains in the pragmatic extreme and others in the explanatory extreme [6] . Although this was an open-label RCT, it was conducted following the EU clinical trials regulation that mandates a number of procedures and processes that distorted the usual patient-physician encounter and the follow-up of participants. The fact that, as has been claimed, there were few exclusions and that some 50% of eligible patients took part in the trial [7] is far from being enough to consider a trial as pragmatic [2] . In addition, it has been recently described that both physicians and patients were subject to behavioral changes due to the Hawthorne effect [8] -something that should be expected to happen to some extent in almost all trials. So, this industry-sponsored phase 3 trial was labelled as Bpragmatic^since its inception, but the term was omitted in the most important paper, the one reporting the results-although other terms intimately associated to Bpragmatic^trials such as Breal-world^and Busual^care were repeatedly mentioned [4] .
In the opposite extreme was the approach taken by the authors of FOCUS that tagged as pragmatic their doubleblind, placebo-controlled trial [9] . This was a multicenter RCT comparing fluoxetine with placebo on functional outcomes after acute stroke published in 2019. Hence, FOCUS was aimed to assess a new indication for a well-known antidepressant. It is almost impossible to believe that a doubleblind, placebo-controlled RCT could resemble real-world practice [2] . Any practicing physician can acknowledge that in usual care patients know-and agree with their physicians-what treatment will they receive. In real-world settings, it is not possible to mask patients and/or physicians in medicine RCTs [10] . Needless to say, it is almost impossible to imagine a situation in which patients will agree to be treated with a placebo. There is no doubt that in FOCUS, both participants and clinicians/investigators were placed in a situation that was very far from normal clinical practice. The explanations of the trial objectives, -a new indication with no regulatory approval granted-, procedures, -including the need for the use of placebo and that participants would have 50% chance of being treated with placebo-, and the informed consent process, were some of the features that prevent correctly tagging this trial as pragmatic. In the follow-up period, investigators checked the adherence to treatment by, among other measures, counting capsules when unused ones were returned: this is not a usual care. By doing this, investigators reported that adherence to treatment by trial participants was superior to that reported in routine clinical practice [9] , a way to acknowledge that FOCUS procedures helped to separate the trial from normal care. Contrary to what happened with the Salford COPD trial, the term Bpragmatic^was not mentioned in any document of the FOCUS trial: neither in the protocol [11] or statistical analysis [12] nor in the information posted on the European (EU-CTR 2011-005616-29) and British (ISRCTN83290762) registries, the latter last edited on October 15, 2018. It seems, therefore, that Bpragmaticŵ as added into the article at the very last minute. The fact that the authors most likely wanted to attract the attention of potential readers by using the term Bpragmatic^is supported by the fact that it was included in the article's title and abstract. But, interestingly enough, it was only mentioned twice in the article's text. FOCUS authors did not provide any explanation as to why this study should be considered pragmatic [9] . No other terms linked to pragmatic RCTs such as Breal-world,B effectiveness,^and Busual (normal) care or clinical practiceŵ ere used in the article. Labeling as Bpragmatic^pre-licensing trials-aiming to assess the efficacy/safety of investigational medicines or of new indications-is misleading. Journal editors should prevent this from happening during the editorial process. A reasonable approach is to limit the use of the adjective Bpragmatic^to those RCTs that showed a high degree of pragmatism by means of the PRECIS-2 tool [1] . At the time of manuscript submission, editors should ask authors to submit, as supplemental information, the assessment of pragmatism by PRECIS-2 tool (providing the scores of the nine domains); if the trial shows to be pragmatic, this assessment should be publicly disclosed to inform readers [2] . For those editors that do not want to engage in this type of exercise, not accepting as pragmatic any masked (participant, physician/ investigator) RCT is strongly suggested. By doing this, editors will educate authors (and readers) in the correct use of this scientific term that ultimately will help the accurate use of it by the clinical trials and regulatory communities.
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